Compare LPSN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPSN | ACET |
|---|---|---|
| Founded | 1995 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.5M | 71.3M |
| IPO Year | 2000 | N/A |
| Metric | LPSN | ACET |
|---|---|---|
| Price | $4.09 | $7.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 202.7K | 187.7K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,660,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.91 | $0.49 |
| 52 Week High | $31.20 | $17.76 |
| Indicator | LPSN | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 38.24 | 97.98 |
| Support Level | $3.91 | $0.47 |
| Resistance Level | $4.18 | $0.52 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.08 | 0.48 |
| Stochastic Oscillator | 11.08 | 94.02 |
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.